1995
Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P, Foster B, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun L, Valdivieso M, Baker L. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clinical Cancer Research 1995, 1: 1487-93. PMID: 9815948.Peer-Reviewed Original ResearchConceptsGrade IV toxicityStarting doseDose escalationClinical trialsPhase I clinical trialNext dose escalationAcceptable toxicity profilePhase II trialDose-limiting toxicityPeak plasma levelsPre-clinical efficacyMultidrug-resistant tumor cellsMurine solid tumorsII trialTreatment coursePlasma levelsGrade IInterpatient variationIntermediate dosePreclinical characteristicsToxicity profilePharmacokinetic parametersDose levelsSolid tumorsTotal dose
1990
Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice
Mucci-LoRusso P, Polin L, Biernat L, Valeriote F, Corbett T. Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Investigational New Drugs 1990, 8: 253-261. PMID: 2177044, DOI: 10.1007/bf00171834.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsCarcinoma, Intraductal, NoninfiltratingColonic NeoplasmsDrug Screening Assays, AntitumorEllipticinesFemaleHumansInjections, IntravenousLeukemia L1210MaleMammary Neoplasms, ExperimentalMiceMice, Inbred StrainsNeoplasm TransplantationNeoplasms, ExperimentalPancreatic Neoplasms